What we're reading, December 30, 2015: most commonly used generic drugs were cheaper at the end of 2015, meanwhile the FDA has a huge backlog of generic drug applications, and few states are expected to expand Medicaid in 2016.
While price hikes for drugs became a topic of much focus in 2015, the reality is that despite the fact that prescription drug spending increased and will continue to grow, many commonly used generic drugs were actually cheaper at the end of the year compared to the beginning. The Washington Post reported that 30 of the 50 most popular generic drugs have declined in price, but Americans are paying more out-of-pocket costs.
Meanwhile, the FDA has a huge backlog of 4300 generic drug applications awaiting approval, according to STAT. The FDA has blamed drugmakers for slowing the process with sloppy and incomplete applications. While many of the backlogged drugs have recently entered the pipeline, some go back to 2009.
Finally, with 20 states that have not yet expanded Medicaid under the Affordable Care Act, the Washington Examiner is expecting few changes in 2016. Governors in only 3 states—South Dakota, Wyoming, and Louisiana—are expected to push for the program’s expansion. With a Democratic governor, Louisiana is the most likely to first make a change. Other states have recently had fierce debates over the right move, but ultimately ended up deadlocked.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More